CERT1 and triple-negative breast carcinoma: Furthermore, COL4A3BP has been identified as one of the 14 genes that confer resistance to paclitaxel treatment in triple-negative breast cancer cells [12] and its expression is associated with worse outcomes in breast cancer, while low CERT expression correlates with better chemotherapeutic outcomes [27].